Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Nils Lachmann"'
Publikováno v:
Frontiers in Genetics, Vol 15 (2024)
IntroductionThe immune response after transplantation depends on recipient/donor HLA allele mismatches. To enhance our understanding of the relations of HLA alleles in terms of amino-acid polymorphisms and shared epitopes, we assessed pairwise sequen
Externí odkaz:
https://doaj.org/article/4f7a464fc14c40f6bac9c4420c5fa791
Autor:
Malte Ziemann, MD, Monika Lindemann, MD, Michael Hallensleben, MD, Wolfgang Altermann, MD, Karina Althaus, MD, Klemens Budde, MD, Gunilla Einecke, MD, Ute Eisenberger, MD, Andrea Ender, PhD, Thorsten Feldkamp, MD, Florian Grahammer, MD, Martina Guthoff, MD, Christopher Holzmann-Littig, MD, Christian Hugo, MD, Teresa Kauke, MD, Stephan Kemmner, MD, Martina Koch, MD, Nils Lachmann, PhD, Matthias Marget, PhD, Christian Morath, MD, Martin Nitschke, MD, Lutz Renders, MD, Sabine Scherer, MD, Julian Stumpf, MD, Vedat Schwenger, MD, Florian Sommer, MD, Bernd Spriewald, MD, Caner Süsal, MD, Daniel Zecher, MD, Falko M. Heinemann, PhD, Murielle Verboom, PhD
Publikováno v:
Transplantation Direct, Vol 10, Iss 9, p e1680 (2024)
Background. Preformed donor-specific HLA antibodies (DSA) are a well-known risk factor in kidney transplantation. There is still considerable debate, however, about the optimal risk stratification among patients with preformed DSA. Additionally, data
Externí odkaz:
https://doaj.org/article/a67c56e5a200414ea670b837dd582929
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectiveIn a cooperative study of the University Hospital Leipzig, University of Leipzig, and the Charité Berlin on kidney transplant patients, we analysed the occurrence of HLA-specific antibodies with respect to the HLA setup of the patients. We
Externí odkaz:
https://doaj.org/article/56e57cd6fe304e57ab0647859babd99c
Autor:
Matthias Niemann, Yara Strehler, Nils Lachmann, Fabian Halleck, Klemens Budde, Gideon Hönger, Stefan Schaub, Benedict M. Matern, Eric Spierings
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Development of donor-specific human leukocyte antigen (HLA) antibodies (DSA) remains a major risk factor for graft loss following organ transplantation, where DSA are directed towards patches on the three-dimensional structure of the respective organ
Externí odkaz:
https://doaj.org/article/bbd636c2afcf480f920489f8af6db569
Autor:
Covadonga López del Moral, Kaiyin Wu, Marcel Naik, Bilgin Osmanodja, Aylin Akifova, Nils Lachmann, Diana Stauch, Sabine Hergovits, Mira Choi, Friederike Bachmann, Fabian Halleck, Eva Schrezenmeier, Danilo Schmidt, Klemens Budde
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
BackgroundDe novo donor-specific HLA antibodies (dnDSA) are key factors in the diagnosis of antibody-mediated rejection (ABMR) and related to graft loss.MethodsThis retrospective study was designed to evaluate the natural course of dnDSA in graft fun
Externí odkaz:
https://doaj.org/article/71fe8385a0cc450eba43f66f76df149a
Autor:
Maria Meneghini, Anna Perona, Elena Crespo, Frederike Bemelman, Petra Reinke, Ondrej Viklicky, Magali Giral, Eduard Palou, Alba Torija, Laura Donadeu, Edoardo Melilli, Jose Zuñiga, Anett Sefrin, Nils Lachmann, Liu Hu, Petra Hruba, Cécile Guillot-Gueguen, Sophie Brouard, Josep Grinyo, Oriol Bestard
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Complete and high-resolution (HR) HLA typing improves the accurate assessment of donor–recipient compatibility and pre-transplant donor-specific antibodies (DSA). However, the value of this information to identify de novo immune-mediated graft even
Externí odkaz:
https://doaj.org/article/7f5cf2b30d89419c885c1cfa441762ca
Autor:
Eva Schrezenmeier, Hector Rincon-Arevalo, Annika Jens, Ana-Luisa Stefanski, Charlotte Hammett, Bilgin Osmanodja, Nadine Koch, Bianca Zukunft, Julia Beck, Michael Oellerich, Vanessa Proß, Carolin Stahl, Mira Choi, Friederike Bachmann, Lutz Liefeldt, Petra Glander, Ekkehard Schütz, Kirsten Bornemann-Kolatzki, Covadonga López del Moral, Hubert Schrezenmeier, Carolin Ludwig, Bernd Jahrsdörfer, Kai-Uwe Eckardt, Nils Lachmann, Katja Kotsch, Thomas Dörner, Fabian Halleck, Arne Sattler, Klemens Budde
Publikováno v:
JCI Insight, Vol 7, Iss 9 (2022)
Transplant recipients exhibit an impaired protective immunity after SARS-CoV-2 vaccination, potentially caused by mycophenolate (MPA) immunosuppression. Recent data from patients with autoimmune disorders suggest that temporary MPA hold might greatly
Externí odkaz:
https://doaj.org/article/581a2764948b4eca936034f6ed975302
Autor:
Berenice Bergel, Tamara Geppert, Beatriz Bañuelos Marco, Frank Friedersdorff, Dominik Müller, Caroline Kempf, Nils Lachmann, Anja Lingnau
Publikováno v:
Frontiers in Surgery, Vol 9 (2022)
IntroductionFrameshift in medical management as well as in surgical thinking is putting the patient as a whole is the focus, rather than just the disease. To optimize the treatment of our pediatric transplant patients in our institution, we changed i
Externí odkaz:
https://doaj.org/article/84386f01310b4c20a0f258b86051e4e5
Autor:
Kaiyin Wu, Danilo Schmidt, Covadonga López del Moral, Bilgin Osmanodja, Nils Lachmann, Fabian Halleck, Mira Choi, Friederike Bachmann, Simon Ronicke, Wiebke Duettmann, Marcel Naik, Eva Schrezenmeier, Birgit Rudolph, Klemens Budde
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
BackgroundTransplant glomerulopathy (TG) may indicate different disease entities including chronic AMR (antibody-mediated rejection). However, AMR criteria have been frequently changed, and long-term outcomes of allografts with AMR and TG according t
Externí odkaz:
https://doaj.org/article/20262ecd9f70436abe164bd3a87e9312
Autor:
Mira Choi, Friederike Bachmann, Kaiyin Wu, Nils Lachmann, Danilo Schmidt, Susanne Brakemeier, Michael Duerr, Andreas Kahl, Kai-Uwe Eckardt, Klemens Budde, Peter Nickel
Publikováno v:
BMC Nephrology, Vol 21, Iss 1, Pp 1-10 (2020)
Abstract Background In de novo kidney transplant recipients (KTR) treatment with belatacept has been established as a comparable option as maintenance immunosuppression, preferably as a strategy to convert from calcineurin inhibitor (CNI)- to belatac
Externí odkaz:
https://doaj.org/article/38dc6b21d0cd4951ab55cf7669822910